William Blair Has Positive Estimate for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Analysts at William Blair raised their Q2 2025 earnings estimates for Charles River Laboratories International in a note issued to investors on Wednesday, May 7th. William Blair analyst M. Smock now forecasts that the medical research company will earn $2.49 per share for the quarter, up from their prior forecast of $2.40. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q4 2025 earnings at $2.52 EPS, FY2025 earnings at $9.79 EPS and FY2026 earnings at $10.83 EPS.

Several other analysts have also commented on CRL. UBS Group reissued a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Mizuho decreased their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating for the company in a research report on Wednesday, April 9th. Redburn Atlantic raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research report on Monday, March 3rd. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and increased their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $176.00.

Charles River Laboratories International Stock Performance

CRL stock opened at $144.38 on Monday. The firm has a market cap of $7.09 billion, a price-to-earnings ratio of 962.53, a PEG ratio of 4.54 and a beta of 1.50. The firm has a 50-day simple moving average of $137.41 and a two-hundred day simple moving average of $165.78. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same period in the prior year, the firm earned $2.27 earnings per share. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year.

Hedge Funds Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rothschild Investment LLC grew its stake in shares of Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company’s stock worth $26,000 after purchasing an additional 144 shares during the period. Brooklyn Investment Group grew its stake in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after purchasing an additional 86 shares during the period. HM Payson & Co. acquired a new stake in shares of Charles River Laboratories International during the 1st quarter worth approximately $31,000. Pinnacle Bancorp Inc. grew its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after purchasing an additional 65 shares during the period. Finally, Optiver Holding B.V. acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth approximately $37,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This represents a 2.83% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42% increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).